Summit Therapeutics Inc. Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets
Summit Therapeutics Inc. (SMMT) reported Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets of GBP 233.00 thousand for the 3-month period ending 2020-03-31, per its 6-K filed 2020-06-02.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets · last filed 2020-06-02
- Summit Therapeutics Inc. expense from equitysettled share-based payment transactions in which goods or services received did not qualify for recognition as assets for the quarter ending 2020-03-31 was 233.00K GBP, a 10.38% decline year-over-year.
- Summit Therapeutics Inc. expense from equitysettled share-based payment transactions in which goods or services received did not qualify for recognition as assets for the quarter ending 2019-03-31 was 260.00K GBP.
| Period end | Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 3 month |
|---|---|
| 2020-03-31 | 233.00K GBP 6-K · filed 2020-06-02 |
| 2019-03-31 | 260.00K GBP 6-K · filed 2020-06-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |